These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk. Mach F; Montecucco F; Steffens S Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689 [TBL] [Abstract][Full Text] [Related]
8. Rimonabant: new data and emerging experience. Wright SM; Dikkers C; Aronne LJ Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988 [TBL] [Abstract][Full Text] [Related]
9. Drug development. Drugs inspired by a drug. Marx J Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309 [No Abstract] [Full Text] [Related]
10. The endocannabinoid system as a novel approach for managing obesity. Lillo JL J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530 [TBL] [Abstract][Full Text] [Related]
11. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? Patti ME J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166 [TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873 [TBL] [Abstract][Full Text] [Related]
13. Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors. Samaha FF; Chou CM Obesity (Silver Spring); 2009 Feb; 17(2):220-5. PubMed ID: 19039319 [No Abstract] [Full Text] [Related]
14. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932 [TBL] [Abstract][Full Text] [Related]
15. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Wierzbicki AS Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677 [TBL] [Abstract][Full Text] [Related]
17. The challenge of treating obesity: the endocannabinoid system as a potential target. Isoldi KK; Aronne LJ J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506 [TBL] [Abstract][Full Text] [Related]
18. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. Sulcová A Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766 [TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system as a target for obesity treatment. Aronne LJ; Pagotto U; Foster GD; Davis SN Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740 [TBL] [Abstract][Full Text] [Related]